----item----
version: 1
id: {81ED46C0-F57D-4D92-9E3C-64F790546A90}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/07/16/AnaptysBio raises $40m for Phase II studies
parent: {C117A4E3-2531-414E-8FEF-96540B531C8B}
name: AnaptysBio raises $40m for Phase II studies
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 7a5d1432-d76a-4939-ab02-d8031693c12b

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 43

AnaptysBio raises $40m for Phase II studies
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 43

AnaptysBio raises $40m for Phase II studies
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1879

<p>San Diego-based AnaptysBio has several antibody discovery partnerships with pharmaceutical and biotechnology companies, but the firm will use its $40m in Series D venture capital financing to run Phase II clinical trials for two of its own therapeutic candidates.</p><p>AnaptysBio's Phase II assets are an anti-Interleukin-33 (IL-33) antibody known as ANB020 for severe adult asthma and peanut allergy, and anti-IL-36 receptor antibody ANB019 for generalized pustular psoriasis. The company also will use its fresh venture cash to finance discovery of new antibody therapeutics using its platform based on in vitro somatic hypermutation.</p><p>The antibody discovery platform has been used to find new product candidates for multiple partners, including <a href="http://www.scripintelligence.com/business/AnaptysBio-partners-with-Celgene-to-deliver-antibody-drug-candidates-329104" target="_new">Celgene</a>, <a href="http://www.scripintelligence.com/business/Selective-AnaptysBio-enters-fourth-antibody-partnership-in-2012-with-Gilead-330030" target="_new">Gilead</a>, <a href="http://www.scripintelligence.com/home/BioNotebook-Gates-Foundation-HalozymeIntrexon-Onconova-Spectrum-AnaptysBioMomenta-348871" target="_new">Momenta</a>, <a href="http://www.scripintelligence.com/home/Tesaro-AnaptysBio-collaborate-on-immune-checkpoint-inhibitors-350634" target="_new">Tesaro</a> and others. Momenta <a href="http://www.scripintelligence.com/business/BioNotebook-Seven-deals-and-updates-including-190-pre-merger-layoffs-at-Auxilium-353786" target="_new">exercised an option</a> for an antibody under its agreement with AnaptysBio in September.</p><p>BVF Partners, BioMed Ventures, Cormorant Asset Management, Frazier Healthcare, HBM Healthcare Investments, Longwood Capital Partners, Novo A/S and other investors backed AnaptysBio's Series D venture funding round.</p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 270

<p>San Diego-based AnaptysBio has several antibody discovery partnerships with pharmaceutical and biotechnology companies, but the firm will use its $40m in Series D venture capital financing to run Phase II clinical trials for two of its own therapeutic candidates.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 43

AnaptysBio raises $40m for Phase II studies
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150716T061200
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150716T061200
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150716T061200
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029244
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 43

AnaptysBio raises $40m for Phase II studies
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{B322F30F-1522-4633-91A4-A2EF3216848C}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359364
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042423Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

7a5d1432-d76a-4939-ab02-d8031693c12b
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042423Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
